Key result
TRPV1 variants identified in patients enhanced calcium release upon anesthetic stimulation in murine models, and the TRPV1 antagonist capsazepine slowed the heat-induced hypermetabolic response.
Why the study?
Does TRPV1 contribute to malignant hyperthermia susceptibility and can its antagonism prevent the hypermetabolic response?
Does TRPV1 contribute to malignant hyperthermia susceptibility and can its antagonism prevent the hypermetabolic response?
TRPV1 variants may confer susceptibility to malignant hyperthermia, and TRPV1 antagonism could represent a novel therapeutic target for its prevention.
This is the authors' abstract. We don't add key points for this paper.
Purpose Malignant hyperthermia (MH) is a pharmacogenetic disorder arising from uncontrolled muscle calcium release due to an abnormality in the sarcoplasmic reticulum (SR) calcium-release mechanism triggered by halogenated inhalational anesthetics. However, the molecular mechanisms involved are still incomplete. Methods We aimed to identify transient receptor potential vanilloid 1( TRPV1 ) variants within the entire coding sequence in patients who developed sensitivity to MH of unknown etiology. In vitro and in vivo functional studies were performed in heterologous expression system, trpv1 −/− mice, and a murine model of human MH. Results We identified TRPV1 variants in two patients and their heterologous expression in muscles of trpv1 −/− mice strongly enhanced calcium release from SR upon halogenated anesthetic stimulation, suggesting they could be responsible for the MH phenotype. We confirmed the in vivo significance by using mice with a knock-in mutation (Y524S) in the type I ryanodine receptor (Ryr1), a mutation analogous to the Y522S mutation associated with MH in humans. We showed that the TRPV1 antagonist capsazepine slows the heat-induced hypermetabolic response in this model. Conclusion We propose that TRPV1 contributes to MH and could represent an actionable therapeutic target for prevention of the pathology and also be responsible for MH sensitivity when mutated.
Answers are grounded in this paper and cite their sources.
TRPV1 may confer malignant hyperthermia susceptibility; leaves open whether antagonism prevents crises in patients.
No takes yet. Share an insight, caveat, or question.
Abeele et al. (2018) studied Malignant hyperthermia (n=2). TRPV1 variants was evaluated on Calcium release from sarcoplasmic reticulum and heat-induced hypermetabolic response. TRPV1 variants identified in patients enhanced calcium release upon anesthetic stimulation in murine models, and the TRPV1 antagonist capsazepine slowed the heat-induced hypermetabolic response.
Synapse has enriched 10 related papers. Consider them for comparative context: